

March 23, 2021

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	--

Dear Sir/Madam,

Subject: Press Release

Please find enclosed a copy of the Press Release titled "Rossari Biotech to Issue Equity Shares aggregating to ₹ 300 Crore on Preferential Basis"

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, Ackruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/111/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000

E info@rossarimail.com W www.rossari.com CIN: L24100MH2009PLC194818



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens,
Kanjurmarg West, Mumbai, Maharashtra 400078

Rossari Biotech to Issue Equity Shares aggregating to ₹ 300 crore on Preferential Basis

Mumbai, March 23, 2021: Rossari Biotech Limited (Rossari), a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries announced that its Board of Directors, in its meeting held today, approved the issuance of up to 30,12,046 equity shares of face value of ₹ 2/- each, on a preferential basis.

The Board of Directors, in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws, determined a floor price of ₹ 996 per Equity Share or such higher price, aggregating to ₹ 300 crore. This preferential issue is subject to necessary approvals, including from the Company's shareholders.

The proposed issue will bring on board high-quality and marquee shareholders of scale and repute. The funds from this issue, if approved, will further strengthen the Company's balance sheet profile and will also augment the financial flexibility to address medium-to-long term growth prospects. Rossari proposes to utilize the net proceeds to evaluate & invest in inorganic growth opportunities, within its core chemistries, with a view to diversify its product portfolio, expand geographical reach and augment end-user industry applications. This will further enable the Company to build a strong upcoming pipeline of new products, with impetus on sustainability and environment-friendliness.

Axis Capital Limited and Axcelus Finserv are advising the Company on this fund raise.

The link to the outcome of the Board meeting, held today, is as follows: [Rossari Biotech – Outcome of Board Meeting](#)

- Ends-

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates 2 manufacturing facilities with a current total capacity of 132,500 MTPA. The units are strategically located at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossarimail.com

Anoop Poojari / Shikha Kshirsagar

CDR India

Tel: +91 98330 90434

Email: anoop@cdr-india.com
shikha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.